The aim of the study was to determine the efficacy of the bismuth drugs in patients with gastric ulcer, receiving cytotoxic therapy. Peptic ulcer, in patients receiving combination chemotherapy, dyspeptic syndrome is characterized by severe, advanced stage and a relatively low degree of chronic gastritis and H. pylori contamination of the gastric mucosa. In patients receiving combination chemotherapy is determined by a significant level of violation of regeneration in the form of atrophy, intestinal metaplasia, dysplasia of the gastric mucosa associated with serious violations of cell homeostasis, under the control of regulatory molecules PCNA, Bcl-2, NF-kB and tachykinins (substance P, neurokinin A). In the subgroup of patients receiving regimens as part of peptic ulcer drugs bismuth less determined violations of the chair (p <0.05) were verified lower rates of expression of factor NF-kB (p<0.05).
Introduction

2
Peptic ulcer (PU) is one of the most wide-spread diseases in therapeutic and gastroenterologic practice. It is considered that 7-10% of adult population on Earth suffers from peptic ulcer [1] . As a rule, PU is associated with H. pylori, infection rate of the population of Russia with which exceeds 50% [1] . There are population groups, morbidity rate of which from the point of vie of PU is higher than average rate of the population. The ulcer genesis may include various factors such as intake of medicines (non-steroid anti-inflammatory drugs, glucocorticosterois, cytostatic drugs) [2] , tuberculosis [3] , chronic obstructive lungs disease, liver cirrhosis, ischemic cardiac disease, anemia [4] , cholecystectomy [5] , accompanied by duodenal reflux [5] . The mentioned patient groups are, as a rule, infected by H. pylori, the role of which in the ulcer genesis may compete with other factors contributing to the forming of peptic ulcers. Pathogenesis of the ulcers connected with the influence of several pathological factors is poorly studied, which prevents from the development of efficient schemes of this suffering treatment. However, availability of various damaging factors in the pathogenesis of PU presupposes the necessity of applying in treatment schemes of cytoprotective drugs, the most prospective of which is bismuth drug [6] . It is shown that in appearance and acute study of PU the special place is taken by dysfunction of diffuse endocrine system and expression of molecules, regulating the process of cellular renovation of epithelial cells of the gastric mucous coat (GMC) (Bcl-2, Ki-67) [7] . The role of PCNA, Bcl-2, NF-Kb and tachykinins is determined (substance P, neurokinin А) in pathogenesis of erosive form of gastroesophagal reflux disease in the case of patients receiving polychemotherapy 3 (PCT) [8] . At that the value of the mentioned regulatory molecules in pathogenesis of peptic ulcer in the case of patients receiving cytostatic therapy is not known [9] .
Determination of the mentioned ulcer genesis aspects allows to optimize anti-ulcer therapy and increase the living standard of the patients.
Study goal: determining the efficiency of bismuth drugs application in the case of patients having gastric ulcer (GU), undergoing cytostatic therapy.
Material and Methods
Total amount of the examined patients with GU is 82. The first group -30 persons -is composed of patients with GU. The second group is composed of 52 patients having GU, suffering from hemoblastosis in the period of full clinical hematological remission of the disease and receiving supporting PCT (GU PCT ). As a control group of the study 30 practically healthy persons were examined complaining insufficiently for setting the diagnosis of functional dyspepsia and lack of macroscopic and microscopic traits of chronic gastritis.
The group of patients with GU has persons having ulcer anamnesis and at the moment of the present examination having recurrence of the disease being infected with H. pylori at the age from 60 to 74. The first group of patients with GU underwent eradication therapy in accordance with Maastricht treaties IV (2010) [10] at the scheme of amoxicillin in the dosage of 1 000 mg 2 times per day, clarithromycin in the dosage of 500 mg 2 times per day and omeprazole in the dosage of 20 mg 2 times per day during 10 days. 4 The 2 nd group of patients having GU had 2 subgroups distinguished. The first subgroup (GU PCT1 ) -30 persons had eradication therapy of the first line in accordance with the above scheme. The 2nd subgroup (GU PCT2 ) -22 persons had eradication therapy in accordance with the scheme of amoxicillin 1 000 mg 2 times per day, clarithromycin in the dosage of 500 mg 2 times per day, omeprazole 20 mg 2 times per day and bismuth drugs in the dosage of 120 mg 4 times per day during 10 days. In lack of effect of the carried out eradication all the patients were appointed eradication quadrotherapy. If markers of H. pylori retained after the second therapy line, the third treatment scheme was appointed taking into account sensitivity of H. pylori to antibiotics. In the 1st group and 1st subgroup of patients having GU receiving PCT omeprazole was appointed in the dosage of 20 mg 2 times per day up to statement of the fact of the ulcer scarring. In the 2 nd subgroup omeprazole therapy was carried out in the dosage of 20 mg 2 times per day and bismuth drugs in the dosage of 120 mg 4 times per day up to the fact statement of the ulcer scarring.
All the patients having GU were examined in accordance with a single program prior to the appointment of eradication therapy and after healing of ulcer defects and reaching elimination of H. pylori. Control group persons were examined one time. Monoclonal Mouse Anti-Human BCL2 Oncoprotein "DACO" (dilution 1:100, incubation time 1 hour at room temperature).
As negative control immunohistochemical reaction was carried out without use of initial antibodies. The specificity of antibodies was proved in control experiments.
The studies were carried out on dewaxed and dehydrated microscopic sections with the use of avidin-biotin immunoperoxidase method. Temperature disclosure of antigens was carried out with the use of 0.01М citrate buffer рН=6.0 under pressure.
For the purpose of blocking endogenous peroxidase laboratory glasses were placed in 3% solution of hydrogen peroxide for 10 minutes. For washing tris-NaCl-buffer was used with рН comprising 7.6. As secondary antibodies those conjugated with polymer were used, marked with peroxidase (universal set DAKO EnVision TM + System).
Stain visualization was carried out with the use of DAB+ complex and substrate buffer.
The evaluation of immunohistochemical dye results was carried out with the help of morphometric study using the system of computer analysis of microscopic images consisting of Nikon Eclipse E400 microscope, Nikon DXM1200 digital camera, PC showed hardly cicatrizing ulcers compared to the group of patients having GU with the same phenomenon typical only of 4 (13.3%) patients. In the subgroup having GU PCT2 6 (27.3%) persons showed hardly cicatrizing ulcers which was of no significant difference (р˃0.05) from the occurrence of hardly cicatrizing ulcers in the subgroup of GU PCT1 .
Results of the Study
In the period of GU remission the group of patients receiving PCT (GU PCT1 ) reliably more frequently (р˃0.05) showed discomfort in epigastric region, belch, epigastric burning, nausea, reduction of appetite, diarrheal syndrome and complaints of weight reduction explained by the effect of the prescribed medicines. The aggregate level of dyspepsia syndrome in the case of patients having GU PCT1 was significantly different (р˃0.05) from that in the case of GU ( from that in the acute disease period (Table 2) . When endoscopic and morphological traits of the disease were compared in the subgroups of patients in the acute phase and remission stage of GU PCT1 and GU PCT2 no significant difference was observed (р˃0.05). 
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Note: "A" letter denotes traits in the period of GU acute stage, "R" letter -in the period of remission. Mark "*" denotes actual difference (р˃0.05) between the analyzed symptoms in the acute period and period of the disease remission. Mark "**" denotes acute difference (р˃0.05) between corresponding symptoms in the acute stage of GU and GU PCT1 . Mark "***" denotes acute difference (р˃0.05) between the analyzed symptoms in the period of GU and 13 GU PCT1 remission, accordingly. In the groups of GU PCT1 and GU PCT2 no actual difference was revealed in the analyzed indicators.
Patients having GU PCT1 showed reliably lower (р<0.05) indicators of expression of PCNA, Р substance and neurokinin А and reliably higher (р<0.05) indicators of expression of Bcl-2 and Nf-kB factor in comparison with the group of patients having GU ( Fig. 1,2) . In the period of GU remission patients of both groups had the tendency of all analyzed immunohistochemical indicators to get normalized. Nevertheless, their values in all cases were reliably different from those of practically healthy persons (Table 3) . When comparing the results of immunohistochemical studies in the subgroups of GU PCT1 and GU PCT2 no reliable difference was discovered (р˃0.05) in no trait. When stating remission in the case of patients having GU PCT2 significantly lower indicators of expression of factor NF-kB were expressed in comparison with those of the patients in GU PCT1 subgroup . . The rest studied immunohistochemical indicators in the remission phase of GU of the persons receiving bismuth drugs in the course of therapy and of the patients receiving no bismuth drugs in the course of therapy were of no statistic difference (р˃0.05). 2.07±0.13**,***** Note: Mark "*" shows actual difference (р˃0.05) between the group of practically healthy persons and patients having GU; mark "**" shows actual difference (р˃0.05) between the period preceding treatment appointment and the period after reaching the disease remission and elimination of H. pylori; mark "***" shows acute difference (р˃0.05) between groups of patients having GU and GU PCT1 in the acute stage of the disease; mark "****" shows actual difference (р˃0.05) between the groups of patients having GU and GU PCT1 in the remission phase; mark "*****"
shows actual difference (р˃0.05) between groups of patients having GU PCT1 and GU PCT2 in the remission phase.
Discussion
Our data testifies of more expressed dyspepsia syndrome of the patients having GU PCT1 , explained by the ability of PCT to have emetogenic effect. indicators which remain changed to a significant extent. At that expression of tachykinins (substance Р, neurokinin А) may keep existing which is described in the literature as the so-called "ex-helicobacter gastritis" capable of long-term persistence, and the disturbed expression of Bcl-2, PCNA, NF-kB progression of chronic gastritis even in the absence of H. pylori [13, 14] . In the subgroup of patients having GU PCT2 the treatment scheme of whom included bismuth drugs stool disorders occurred reliably less frequently in the form of diarrheal syndrome (р<0.05), which was explained by the ability of this group of drugs to absorb bacterial toxins, inhibit the growth of pathological microflora and reduce the production of anti-inflammatory prostaglandins enhancing intestinal peristalsis [15] . The patients receiving bismuth drugs in the treatment scheme reliable lower indicators (р<0.05) of factor NF-kB expression were distinguished, which testified of positive influence of this drug group on cell homeostasis of GMC. At that no reliable difference in evolution of endoscopic and morphological traits of GU in different subgroups of patients having GU was distinguished from the point of view of evolution of endoscopic and morphological evidence of GU in different subgroups of GU patients receiving PCT (р˃0.05). 
